-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Immunovant, Raises Price Target to $61

Benzinga·06/30/2026 18:49:14
Listen to the news
Citigroup analyst Samantha Semenkow maintains Immunovant (NASDAQ:IMVT) with a Buy and raises the price target from $57 to $61.